These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3426390)

  • 1. Androgen levels and sex functions in testosterone-treated hypogonadal men.
    Gooren LJ
    Arch Sex Behav; 1987 Dec; 16(6):463-73. PubMed ID: 3426390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study.
    Skakkebaek NE; Bancroft J; Davidson DW; Warner P
    Clin Endocrinol (Oxf); 1981 Jan; 14(1):49-61. PubMed ID: 7014044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone undecanoate: a new orally active androgen.
    Hirschhäuser C; Hopkinson CR; Sturm G; Coert A
    Acta Endocrinol (Copenh); 1975 Sep; 80(1):179-87. PubMed ID: 1098350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
    Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
    J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
    Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
    Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypogonadal men treated with oral testosterone undecanoate.
    Sarris S; Swyer GI; Lawrence DM
    Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen replacement therapy: present and future.
    Gooren LJ; Bunck MC
    Drugs; 2004; 64(17):1861-91. PubMed ID: 15329035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A ten-year safety study of the oral androgen testosterone undecanoate.
    Gooren LJ
    J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.
    Yin AY; Htun M; Swerdloff RS; Diaz-Arjonilla M; Dudley RE; Faulkner S; Bross R; Leung A; Baravarian S; Hull L; Longstreth JA; Kulback S; Flippo G; Wang C
    J Androl; 2012; 33(2):190-201. PubMed ID: 21474786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes.
    Morales A; Johnston B; Heaton JP; Lundie M
    J Urol; 1997 Mar; 157(3):849-54. PubMed ID: 9072584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone treatment of hypogonadal men participating in competitive sports.
    Gooren LJ; Behre HM
    Andrologia; 2008 Jun; 40(3):195-9. PubMed ID: 18477208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which testosterone replacement therapy?
    Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial trial of slow-release testosterone microspheres in hypogonadal men.
    Burris AS; Ewing LL; Sherins RJ
    Fertil Steril; 1988 Sep; 50(3):493-7. PubMed ID: 3410101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.